What the label states, the lot delivers — net peptide mass, not gross powder weight, purity reported as measured rather than rounded up, and a Certificate of Analysis for every lot.
Net peptide mass, not powder weight; purity as measured, not rounded up; a COA per lot.
Net peptide + purity not rounded up. COA per lot.
FDA PCAC reviews 7 peptides for the 503A bulks list (BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, Epitalon). Read our compounder's decision tree. Read our briefing →
FDA PCAC reviews 7 peptides for the 503A bulks list in July. Read →
FDA PCAC: 7 peptides under review. Read →
Gonadotropin glycoprotein hormone · heavily regulated
Vialdyne primary owner
This is the primary page for HCG buyers who need a regulated procurement discussion rather than a broad catalog listing. It should help the pharmacy buyer confirm documentation depth, market-fit review, batch identity, and whether the requested presentation belongs in the buyer's quality system.
Overview
Human Chorionic Gonadotropin (HCG) is a heterodimeric glycoprotein hormone, produced natively by placental syncytiotrophoblast cells during pregnancy. The structural make-up is a 92-residue alpha-subunit (shared across FSH, LH, and TSH) non-covalently associated with a 145-residue HCG-specific beta-subunit; both subunits carry extensive glycosylation. Functionally, the molecule mimics LH activity at the LH/HCG receptor and carries prescription-drug approval across three clinical indications: ovulation induction, hypogonadotropic hypogonadism in males, and paediatric cryptorchidism. Active material is sourced through one of two routes, purification from pregnancy urine (the historical method) or recombinant cell-culture expression, and the two sources diverge in glycosylation pattern, requiring source-specific identity confirmation at the receiving QA step. For compounding pharmacy and distributor buyers, Vialdyne distributes HCG only to qualified buyers carrying appropriate import and dispensing licensing in the destination jurisdiction; every order routes through upfront compliance review before lot reservation. Eight catalogue fills span both IU-based presentations (1000-10000 IU range) and mass-based presentations (1-10 mg range) to accommodate the dual dosing conventions used across clinical and research workflows. The release packet leans on biological activity (IU per mg, determined by bioassay) rather than chromatographic purity alone, this is essential because heterodimer integrity and glycosylation pattern jointly affect potency in ways that RP-HPLC purity simply cannot capture.
Applications & buyer fit
Custom-blend buyers are almost always OEM clients building a branded product around a specific ratio of two or more peptides. The development workflow is collaborative: ratio target, analytical method to verify it, stability protocol in the chosen carrier, and packaging selection are all defined in the OEM brief before the first commercial run. Sample-stage volumes are usually 5-10 g of finished blend; commercial MOQ depends on the components.
Sourced for
Buyer fit
Documentation that ships
Procurement note: Ratio target, the analytical method to verify it, stability protocol, and packaging are defined in the OEM brief before the first commercial run.
Primary buyer fit: 503A / 503B compounding pharmacies and regional distributors and re-sellers.
Specifications
Certificate of Analysis
Published released-batch COAs for HCG (Human Chorionic Gonadotropin), every lot HPLC-verified. These are previews — request the full high-resolution certificate for any lot.
VerifiedRequest full COA →HCG (Human Chorionic Gonadotropin)
VD260428-HCG10K093 · 99.39%
VerifiedRequest full COA →HCG (Human Chorionic Gonadotropin)
VD260428-HCG1K090 · 99.23%
VerifiedRequest full COA →HCG (Human Chorionic Gonadotropin)
VD260428-HCG2K091 · 99.52%
VerifiedRequest full COA →HCG (Human Chorionic Gonadotropin)
VD260428-HCG5K092 · 98.95%
Regulatory note
A heterodimeric glycoprotein hormone that is highly regulated. We supply it exclusively to qualified buyers holding the appropriate licensing for their jurisdiction, and every order is subject to compliance review before it proceeds.
Selected literature
Frequently asked questions
As a glycoprotein hormone HCG is more fragile than a synthetic peptide, so keep the sealed lyophilised vial refrigerated or frozen per the certificate's stated condition, protected from moisture, with the re-test date documented on the released-batch record. Reconstitute in the labelled diluent immediately before use inside a sterile field for injectable IU fills, and avoid vigorous agitation that can denature the glycoprotein. Prepare single-use aliquots and minimise repeated freeze-thaw, since activity loss in glycoproteins tracks handling stress. A documented cold-chain excursion should prompt a bioassay re-check before the lot is released.
Because biological activity depends on glycosylation as much as protein mass, the operative number is the batch-specific bioassay-determined IU/mg printed on the certificate, not a generic conversion. Request that bioassay potency result alongside an identity confirmation and the source designation, since urinary-derived and recombinant material carry different glycan profiles and specific activities. For IU-based injectable fills, extend the same released lot to endotoxin and microbial-limits testing appropriate to a sterile product. Having bioassay potency, identity, source, and sterility data on one certificate lets a pharmacy fill against IU with confidence rather than inferring activity from mass.
Related peptides
